Release Date: 04-Sep-2014
“UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related to pharmaceutical market:
According to estimates, diabetes has been termed as a “pandemic disease” within the Middle east and North Africa (MENA) countries and among the GCC countries. In the MENA region, approximately 32.8 million people have been diagnosed with diabetes in 2011-12. In this region, 6 countries, namely, Bahrain, Egypt, Kuwait, Oman, Saudi Arabia and the United Arab Emirates (UAE), are ranked among the world’s top 10 countries with a high prevalence of diabetes and impaired glucose tolerance. It is expected that approximately 4% of deaths in this region would be due to diabetes by 2030, which is an increase of more than 80% from 2008 figures.
UAE, with one of the highest rates of type 2 diabetes, represents significant societal costs, in relation to morbidity, mortality and also lost productivity coupled with a huge burden on the healthcare system. It has been observed that the high prevalence of diabetes in the UAE is gradually taking its toll on the overall health of the nation and also risking the country’s economic well-being.
The total number of diabetes patients in the stood at 7,45,000 in 2013. With factors such as obesity, rising sedentary lifestyles and unhealthy diet acting in full force, it is expected that the number of diabetic patients in the UAE would grow at a CAGR of 4-6%, which is double the growth rate of the global market. The number of diabetics in the UAE is expected to more than 8,50,000 by 2017. This growth in the number of diabetics in the country would invariably propel the growth of diabetes care devices market, which includes insulin products and glucose level monitor market.
For Report Sample Visit: UAE Diabetes Market Opportunity Analysis 2018
Or Contact: email@example.com